Read by QxMD icon Read

Chaitanya Divgi

Chaitanya R Divgi
No abstract text is available yet for this article.
December 6, 2018: Academic Radiology
E David Crawford, Phillip J Koo, Neal Shore, Susan F Slovin, Raoul S Concepcion, Stephen J Freedland, Leonard G Gomella, Lawrence Karsh, Thomas E Keane, Paul Maroni, David Penson, Daniel P Petrylak, Ashley Ross, Vlad Mouraviev, Robert E Reiter, Chaitanya Divgi, Evan Y Yu
PURPOSE: The advanced prostate cancer therapeutic landscape has changed dramatically in the last several years, resulting in improved overall survival of patients with castration naive and castration resistant disease. The evolution and development of novel next generation imaging techniques will affect diagnostic and therapeutic decision making. Clinicians must navigate when and which next generation imaging techniques to use and how to adjust treatment strategies based on the results, often in the absence of correlative therapeutic data...
January 18, 2019: Journal of Urology
Chaitanya Divgi
No abstract text is available yet for this article.
November 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Chaitanya Divgi
No abstract text is available yet for this article.
January 2018: European Journal of Nuclear Medicine and Molecular Imaging
Francesca Rapido, Gary M Brittenham, Sheila Bandyopadhyay, Francesca La Carpia, Camilla L'Acqua, Donald J McMahon, Abdelhadi Rebbaa, Boguslaw S Wojczyk, Jane Netterwald, Hangli Wang, Joseph Schwartz, Andrew Eisenberger, Mark Soffing, Randy Yeh, Chaitanya Divgi, Yelena Z Ginzburg, Beth H Shaz, Sujit Sheth, Richard O Francis, Steven L Spitalnik, Eldad A Hod
BACKGROUND: Some countries have limited the maximum allowable storage duration for red cells to 5 weeks before transfusion. In the US, red blood cells can be stored for up to 6 weeks, but randomized trials have not assessed the effects of this final week of storage on clinical outcomes. METHODS: Sixty healthy adult volunteers were randomized to a single standard, autologous, leukoreduced, packed red cell transfusion after 1, 2, 3, 4, 5, or 6 weeks of storage (n = 10 per group)...
January 3, 2017: Journal of Clinical Investigation
Masatoshi Shiono, Kan Huang, Robert J Downey, Nikita Consul, Nicolas Villanueva, Kristen Beck, Kathleen Fenn, Donald Dietz, Takuhiro Yamaguchi, Shunsuke Kato, Chaitanya Divgi, Kevin Kalinsky, Ying Wei, Yuan Zhang, Alain C Borczuk, Akira Inoue, Balazs Halmos, Swarnali Acharyya
Weight loss and hematogenous metastases are poor prognosis factors in lung cancer patients that can but do not necessarily co-occur. We retrospectively investigated the clinical association between cachexia, tumor characteristics (such as metastatic burden and mutational status), and treatment in lung cancer patients. The medical records of 394 lung cancer patients from two institutions (Columbia University, USA and Tohoku University, Japan) were reviewed. Information collected included the presence of cachexia, histologic subtype, tumor stage, number of metastases, mutation status, treatment, and survival...
September 2016: Cancer Medicine
Chaitanya Divgi
No abstract text is available yet for this article.
February 2016: Academic Radiology
Sheldon Feldman, Hannah Bansil, Jeffrey Ascherman, Robert Grant, Billie Borden, Peter Henderson, Adewuni Ojo, Bret Taback, Margaret Chen, Preya Ananthakrishnan, Amiya Vaz, Fatih Balci, Chaitanya R Divgi, David Leung, Christine Rohde
BACKGROUND: As many as 40 % of breast cancer patients undergoing axillary lymph node dissection (ALND) and radiotherapy develop lymphedema. We report our experience performing lymphatic-venous anastomosis using the lymphatic microsurgical preventive healing approach (LYMPHA) at the time of ALND. This technique was described by Boccardo, Campisi in 2009. METHODS: LYMPHA was offered to node-positive women with breast cancer requiring ALND. Afferent lymphatic vessels, identified by injection of blue dye in the ipsilateral arm, were sutured into a branch of the axillary vein distal to a competent valve...
October 2015: Annals of Surgical Oncology
Pat Zanzonico, Jorge A Carrasquillo, Neeta Pandit-Taskar, Joseph A O'Donoghue, John L Humm, Peter Smith-Jones, Shutian Ruan, Chaitanya Divgi, Andrew M Scott, Nancy E Kemeny, Yuman Fong, Douglas Wong, David Scheinberg, Gerd Ritter, Achem Jungbluth, Lloyd J Old, Steven M Larson
PURPOSE: The molecular specificity of monoclonal antibodies (mAbs) directed against tumor antigens has proven effective for targeted therapy of human cancers, as shown by a growing list of successful antibody-based drug products. We describe a novel, nonlinear compartmental model using PET-derived data to determine the "best-fit" parameters and model-derived quantities for optimizing biodistribution of intravenously injected (124)I-labeled antitumor antibodies. METHODS: As an example of this paradigm, quantitative image and kinetic analyses of anti-A33 humanized mAb (also known as "A33") were performed in 11 colorectal cancer patients...
October 2015: European Journal of Nuclear Medicine and Molecular Imaging
Neeta Pandit-Taskar, Joseph A O'Donoghue, Chaitanya R Divgi, Eze A Wills, Lawrence Schwartz, Mithat Gönen, Peter Smith-Jones, Neil H Bander, Howard I Scher, Steven M Larson, Michael J Morris
BACKGROUND: J591 is a monoclonal antibody that targets the external domain of the prostate-specific membrane antigen (PSMA). Besides prostate cancer cells, it also targets the neovasculature of non-prostate solid tumors. We provide an analysis of the antibody mass-dose dependency of lesion uptake and normal tissue retention, together with an assessment of lesion detectability using (111)In-J591 imaging, compared with conventional imaging in patients with a variety of solid tumors. METHODS: Twenty patients in six cohorts received fixed amounts (5, 10, 20, 40, 60, and 100 mg) of J591 in a phase I trial...
2015: EJNMMI Research
Matthew J Pianko, Evangelos Terpos, G David Roodman, Chaitanya R Divgi, Sonja Zweegman, Jens Hillengass, Suzanne Lentzsch
Detection of lytic bone lesions is crucial in the workup for multiple myeloma and very often dictates the decision to start treatment. Conventional radiography, despite decades of use, is often insufficient for detection of bone disease in multiple myeloma. Modern imaging techniques such as MRI, PET, and CT offer superior detection of myeloma bone disease and extramedullary manifestations of plasma cell dyscrasias. Novel whole-body low-dose computed tomography (WBLDCT) protocols allow for collection of superior image detail of the skeleton at doses of radiation similar to those used for conventional planar radiography...
December 1, 2014: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
David Leung, Saravanan Krishnamoorthy, Lawrence Schwartz, Chaitanya Divgi
INTRODUCTION: In conjunction with biomarkers, imaging is an important component of the diagnostic work up and subsequent management of men with prostate cancer. MATERIALS AND METHODS: The relevant literature was retrieved from a search of MEDLINE with appropriate key words. RESULTS: Osseous metastases develop in close to 90% of patients with metastatic prostate cancer, thus making bone scans (single photon, using Tc-99m labeled phosphonates) the mainstay of imaging in advanced prostate cancer...
April 2014: Canadian Journal of Urology
Chunsheng Li, Ann-Marie Chacko, Jia Hu, Kosei Hasegawa, Jennifer Swails, Luigi Grasso, Wafik S El-Deiry, Nicholas Nicolaides, Vladimir R Muzykantov, Chaitanya R Divgi, George Coukos
UNLABELLED: Tumor endothelial marker 1 (TEM1, endosialin) is a tumor vascular marker with significant diagnostic and therapeutic potential. However, in vivo small animal models to test affinity reagents specifically targeted to human (h)TEM1 are limited. We describe a new mouse tumor model where tumor vascular endothelial cells express hTEM1 protein. METHODS: Immortalized murine endothelial cells MS1 were engineered to express hTEM1 and firefly luciferase and were inoculated in nude mice either alone, to form hemangioma-like endothelial grafts, or admixed with ID8 ovarian tumor cells, to form chimeric endothelial-tumor cell grafts...
April 2014: Cancer Biology & Therapy
Ann-Marie Chacko, Chunsheng Li, Madhura Nayak, John L Mikitsh, Jia Hu, Catherine Hou, Luigi Grasso, Nicholas C Nicolaides, Vladimir R Muzykantov, Chaitanya R Divgi, George Coukos
UNLABELLED: Tumor endothelial marker 1 (TEM1/endosialin) is a tumor vascular marker highly overexpressed in multiple human cancers with minimal expression in normal adult tissue. In this study, we report the preparation and evaluation of (124)I-MORAb-004, a humanized monoclonal antibody targeting an extracellular epitope of human TEM1 (hTEM1), for its ability to specifically and sensitively detect vascular cells expressing hTEM1 in vivo. METHODS: MORAb-004 was directly iodinated with (125)I and (124)I, and in vitro binding and internalization parameters were characterized...
March 2014: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Belinda Seto, Paula M Jacobs, Robert H Mach, Jeff Wm Bulte, Weibo Cai, Abass Alavi, Chaitanya R Divgi, Joseph C Wu
No abstract text is available yet for this article.
2013: American Journal of Nuclear Medicine and Molecular Imaging
Chaitanya Divgi
No abstract text is available yet for this article.
January 2014: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Christine A Ciunci, Rodolfo F Perini, Anjali N Avadhani, Hyunseon C Kang, Weijing Sun, Maryann Redlinger, Kathleen Harlacker, Keith T Flaherty, Bruce J Giantonio, Mark A Rosen, Chaitanya R Divgi, Hee Kwon Song, Sarah Englander, Andrea Troxel, Mitchell Schnall, Peter J O'Dwyer
BACKGROUND: Preclinical and clinical studies suggest mTOR (mammalian target of rapamycin) inhibitors may have metabolic and antiangiogenic effects, and synergize with epidermal growth factor pathway inhibitors. Therefore, a phase 1/pharmacodynamic trial of everolimus with cetuximab was performed. METHODS: A total of 29 patients were randomized to a run-in of oral everolimus (30, 50, or 70 mg) or cetuximab (400 mg/m(2) loading, 250 mg/m(2) maintenance) weekly, followed by the combination in this dose-escalation study...
January 1, 2014: Cancer
Joseph A O'Donoghue, José G Guillem, Heiko Schöder, Nancy Y Lee, Chaitanya R Divgi, Jeannine A Ruby, John L Humm, Steven A Lee-Kong, Eva M Burnazi, Shangde Cai, Sean D Carlin, Tobias Leibold, Pat B Zanzonico, C Clifton Ling
BACKGROUND: Hypoxia within solid tumors confers radiation resistance and a poorer prognosis. 124I-iodoazomycin galactopyranoside (124I-IAZGP) has shown promise as a hypoxia radiotracer in animal models. We performed a clinical study to evaluate the safety, biodistribution, and imaging characteristics of 124I-IAZGP in patients with advanced colorectal cancer and head and neck cancer using serial positron emission tomography (PET) imaging. METHODS: Ten patients underwent serial whole-torso (head/neck to pelvis) PET imaging together with multiple whole-body counts and blood sampling...
June 3, 2013: EJNMMI Research
Anthony T Corcoran, Paul Russo, William T Lowrance, Aviva Asnis-Alibozek, John A Libertino, Daniel A Pryma, Chaitanya R Divgi, Robert G Uzzo
OBJECTIVE: To clearly define the proportions of benign vs malignant histologic findings in resected renal masses through an in-depth review of the contemporary medical data to assist in preoperative risk assessment. MATERIALS AND METHODS: PubMed and select oncology congresses were searched for publications that identify the histologic classification of resected renal masses in a representative sample from the contemporary data: [search] incidence AND (renal cell carcinoma AND benign); incidence AND (renal tumor AND benign); percentage AND (renal cell carcinoma AND benign); limit 2003-2011...
April 2013: Urology
Chaitanya R Divgi, Robert G Uzzo, Constantine Gatsonis, Roman Bartz, Silke Treutner, Jian Qin Yu, David Chen, Jorge A Carrasquillo, Steven Larson, Paul Bevan, Paul Russo
PURPOSE: A clinical study to characterize renal masses with positron emission tomography/computed tomography (PET/CT) was undertaken. PATIENTS AND METHODS: This was an open-label multicenter study of iodine-124 ((124)I) -girentuximab PET/CT in patients with renal masses who were scheduled for resection. PET/CT and contrast-enhanced CT (CECT) of the abdomen were performed 2 to 6 days after intravenous (124)I-girentuximab administration and before resection of the renal mass(es)...
January 10, 2013: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"